10-Q: GlobeStar Therapeutics Reports Q1 2024 Results: No Revenue, Continued Losses, and Going Concern Uncertainty

GlobeStar Therapeutics Corporation reports no revenue and a net loss of $163,759 for the quarter ended December 31, 2023, with substantial doubt about its ability to continue as a going concern.

Summary

• GlobeStar Therapeutics Corporation reported its financial results for the quarter ended December 31, 2023.
• The company had no revenue during the quarter.
• The net loss for the quarter was $163,759, compared to a net loss of $165,909 for the same period in 2022.
• General and administrative expenses were $155,871, slightly higher than the $155,241 reported in the previous year.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern due to negative working capital of $1,532,533 and minimal revenue.
• Management plans to address the financial situation by seeking debt financing and focusing on raising funds to implement the business plan.
• As of March 11, 2024, there were 1,162,921,101 shares of common stock issued and outstanding.
• The company is developing an expanded platform of products that include addition of treatment for Multiple Sclerosis and other neurodegenerative diseases.

Sentiment

Score: 2

Explanation: The document presents a negative outlook due to the company's lack of revenue, net losses, negative working capital, and going concern uncertainty. While there are some positive aspects, such as the company's efforts to secure financing and expand its product platform, the overall sentiment is poor.

Positives

• The company is actively seeking financing to support its operations and business plan.
• GlobeStar Therapeutics is expanding its product platform to include treatments for Multiple Sclerosis and other neurodegenerative diseases, potentially opening new revenue streams.
• The company has entered into a consulting agreement with Advanced Innovate Partners (AIP) under which AIP will provide advice to GlobeStar and SMIHC on the global design, strategy and execution of clinical trials.

Negatives

• The company reported no revenue for the quarter ended December 31, 2023.
• The company has a net loss of $163,759 for the quarter ended December 31, 2023.
• The company has negative working capital of $1,532,533.
• Auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of December 31, 2023.
• The company did not maintain effective controls over the control environment as of December 31, 2023.
• The company did not maintain effective controls over financial statement disclosure as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is uncertain due to its financial condition.
• The company may not be able to secure additional financing on acceptable terms or at all.
• The company's planned activities may not be successful, and it may not achieve profitability.
• The company's disclosure controls and procedures are not effective, which could lead to errors or fraud.
• The company is subject to routine litigation, claims, or disputes in the ordinary course of business.

Future Outlook

Management plans to continue focusing on raising funds necessary to implement the company's business plan and will continue to seek out debt financing to obtain the capital required to meet the company's financial obligations; in the midterm, management will enhance its capital position with a public offering of equity securities to finance clinical trials and the necessary actions to obtain approval of worldwide marketing of our MS treatment; in the long term, marketing the company's pharmaceutical and nutraceutical products will provide the necessary cash flow to support future growth.

Management Comments

• Management plans to continue to focus on raising the funds necessary to implement the Company's business plan.
• Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations.
• Management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company's future growth.

Industry Context

GlobeStar Therapeutics is operating in the pharmaceutical industry, specifically targeting the treatment of Multiple Sclerosis and other neurodegenerative diseases, which is a competitive and highly regulated market. The company's success depends on its ability to secure funding, complete clinical trials, and obtain regulatory approvals.

Comparison to Industry Standards

• Given the lack of revenue and the going concern warning, GlobeStar's financial performance is significantly below industry standards for pharmaceutical companies, especially those in the clinical stage.
• Comparable companies with similar market capitalizations often have ongoing revenue streams from existing products or licensing agreements, which GlobeStar currently lacks.
• The company's reliance on debt financing and equity offerings to fund its operations is a common strategy for early-stage pharmaceutical companies, but the going concern warning indicates a higher level of risk compared to its peers.
• Companies like Biohaven Pharmaceutical (now part of Pfizer) and Neurocrine Biosciences, which focus on neurological disorders, serve as benchmarks for clinical development and regulatory approval processes, highlighting the challenges and costs associated with bringing new treatments to market.

Related Party Transactions

• As of December 31, 2023 and September 30, 2023, the Company owed $ 504,715 and $ 454,665 to officers of the Company for compensation which are recorded as accounts payable related party.
• During the three months ended December 31, 2023 and 2022 the Company received short term, unsecured, non-interest bearing advances from the Companys CEO totaling $ 300 and $ 500 , respectively.
• The Company awarded Mr. Katzaroff a total of 35,000,000 common stock options with an exercise price of $ 0.009 per share, an exercise term of five years.
• On September 26, 2023, the Company entered into an agreement with SMI HealthCare LLC (SMIHC) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East, excluding Israel and Iraq, and for government and private aid organizations, for the Company's patented Multiple Sclerosis treatment.
• On September 19, 2023, the Company entered into a supplement to employment agreement with Jim Katzaroff, the CEO.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential layoffs or restructuring if the company cannot secure additional financing.
• Customers and partners may be impacted by delays or cancellations of product development and commercialization efforts.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional financing to continue its operations.
• The company needs to complete clinical trials and obtain regulatory approvals for its Multiple Sclerosis treatment.
• The company needs to improve its disclosure controls and procedures.
• The company needs to address the material weaknesses in its internal controls over financial reporting.

Key Dates

Keywords

Therapeutics, GlobeStar, Financials, Going Concern, Multiple Sclerosis, Pharmaceutical, Net Loss, Convertible Notes, Financing, Operations